Market Performance - U.S. stocks showed mixed performance, with the Dow Jones index increasing by 0.54% to 49,261.60, while the NASDAQ fell by 0.62% to 23,437.73 and the S&P 500 dropped by 0.05% to 6,917.76 [1] - Industrial shares rose by 1.4% on Thursday, indicating strength in that sector [1] Sector Performance - Information technology stocks decreased by 1.4% on Thursday [2] Commodities - Oil prices increased by 1.8% to $56.98, while gold prices slightly decreased by 0.1% to $4,456.70. Silver fell by 3.6% to $74.820, and copper dropped by 1.7% to $5.7600 [6] European Market - European shares were mixed, with the eurozone's STOXX 600 declining by 0.27%, while Spain's IBEX 35 Index rose by 0.27%. London's FTSE 100 fell by 0.06%, Germany's DAX decreased by 0.08%, and France's CAC 40 increased by 0.06% [7] Asian Market - Asian markets closed lower, with Japan's Nikkei 225 down by 1.63%, Hong Kong's Hang Seng Index declining by 1.17%, China's Shanghai Composite slipping by 0.07%, and India's BSE Sensex falling by 0.92% [10] Company News - Flyexclusive Inc shares surged by 126% to $7.10 after being named an authorized Starlink Aviation dealer [9] - Enliven Therapeutics Inc shares increased by 54% to $23.81 following positive initial data from a clinical trial for chronic myeloid leukemia [9] - MoonLake Immunotherapeutics shares rose by 29% to $14.54 after receiving FDA feedback on its treatment for hidradenitis suppurativa [9] - Immuneering Corp shares dropped by 39% to $5.10 after announcing updated trial data for pancreatic cancer [9] - Acrivon Therapeutics Inc shares fell by 31% to $2.05 after releasing clinical data for endometrial cancer [9] - CorMedix Inc shares decreased by 23% to $8.00 following preliminary revenue results for Q4 and FY25 [9] Economic Indicators - U.S. initial jobless claims rose by 8,000 to 208,000, slightly below market expectations of 210,000 [3][12] - Nonfarm business sector labor productivity increased by 4.9% in Q3, following a revised 4.1% gain in the previous quarter [12] - Unit labor costs in the nonfarm business sector fell by 1.9% in Q3, contrasting with market expectations of a 1.0% increase [12] - The U.S. trade deficit narrowed to $29.4 billion in October, the smallest since June 2009, compared to a revised $48.1 billion in September [12]

Market Overview - U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow decreased by 0.05% to 48,972.29, the NASDAQ declined by 0.57% to 23,448.86, and the S&P 500 fell by 0.14% to 6,911.57 [1] - Information technology stocks dipped by 1.4% on Thursday [2] - European shares were mostly lower, with the eurozone's STOXX 600 slipping 0.3% [7] - Asian markets closed lower, with Japan's Nikkei 225 falling 1.63% [9] Company Performance - Acuity Inc. (NYSE:AYI) reported fiscal first-quarter 2026 results, achieving a 20.2% year-over-year net sales growth to $1.14 billion, in line with analyst expectations. The adjusted EPS was $4.69, surpassing the consensus estimate of $4.59 [3] - Flyexclusive Inc. (NYSE:FLYX) shares surged 126% to $7.44 after being named an authorized Starlink Aviation dealer [8] - Enliven Therapeutics Inc. (NASDAQ:ELVN) shares increased by 59% to $24.55 following positive initial data from a Phase 1b clinical trial [8] - Nuvve Holding Corp. (NASDAQ:NVVE) shares rose by 46% to $5.11 after regaining Nasdaq compliance [8] - Immuneering Corp. (NASDAQ:IMRX) shares dropped 35% to $5.45 after announcing updated survival and safety data from a Phase 2a trial [8] - Acrivon Therapeutics Inc. (NASDAQ:ACRV) shares fell 29% to $2.10 after announcing clinical data related to endometrial cancer [8] - CorMedix Inc. (NASDAQ:CRMD) shares decreased by 25% to $8.33 following preliminary revenue results [8] Commodities - Oil prices increased by 1.9% to $57.03, while gold prices decreased by 0.6% to $4,436.20. Silver fell by 4.7% to $73.925, and copper dropped by 2.5% to $5.7120 [6]

Core Insights - U.S. stock futures are lower, with Dow futures dropping over 100 points on Thursday [1] - Immuneering Corp's shares fell 20.7% to $6.61 in pre-market trading following the announcement of updated survival and safety data from its Phase 2a trial for pancreatic cancer [1] Company Movements - Elme Communities shares decreased 82.8% to $2.98 in pre-market trading [3] - Erasca Inc shares fell 14% to $4.45 after a previous rise of 42% on Wednesday [3] - Phathom Pharmaceuticals Inc shares dropped 13.7% to $15.60 after announcing a $130 million public offering [3] - United Microelectronics Corp shares declined 6.3% to $8.37 after a 10% increase on Wednesday due to reported sales growth [3] - Canadian Solar Inc shares decreased 6.1% to $20.68 following a proposed $200 million public offering [3] - Trevi Therapeutics Inc shares fell 6.1% to $11.00 in pre-market trading [3] - Revolution Medicines Inc shares dipped 6% to $96.57 after reports that AbbVie is not in discussions with the company [3] - Sibanye Stillwater Ltd shares decreased 5.7% to $15.01 in pre-market trading [3] - Vanda Pharmaceuticals Inc shares fell 5% to $8.11 despite FDA approval of its product to prevent motion-induced vomiting [3] - Logitech International SA shares declined 4.8% to $94.91 ahead of its third quarter fiscal year 2026 financial results release [3]

Company Performance - AZZ Inc reported adjusted earnings of $1.52 per share, exceeding market estimates of $1.47 per share [1] - The company's sales reached $425.746 million, surpassing expectations of $418.164 million [1] - AZZ shares increased by 2.1% to $112.09 in pre-market trading following the earnings report [1] Notable Stock Movements - CIMG Inc gained 33.3% to $1.44 after securing approximately $124 million in commercial contracts [4] - ECD Automotive Design Inc rose 26.4% to $0.59 due to talks for strategic deals valued between $2 million and $10 million [4] - Acrivon Therapeutics Inc increased by 22.1% to $3.60, announcing a clinical update on its ongoing studies [4] - Nuvve Holding Corp gained 17.1% to $4.11 after a previous 60% rise [4] - RenovoRx Inc surged 16.8% to $1.18 in pre-market trading [4] - Serina Therapeutics Inc rose 16.4% to $2.82 after a 15% increase on Wednesday [4] - Super League Enterprise Inc increased by 11.2% to $0.68 following an asset purchase agreement [4] - Northrop Grumman Corp gained 6.8% to $616.26, influenced by a potential increase in the military budget [4] Declining Stocks - Immuneering Corp fell 20.7% to $6.61 after announcing updated trial data [4] - Erasca Inc decreased by 14% to $4.45 after a previous 42% rise [4] - Phathom Pharmaceuticals Inc dropped 13.7% to $15.60 following a $130 million public offering announcement [4] - United Microelectronics Corp fell 6.3% to $8.37 after a previous 10% increase [4]

此外，该联合疗法的12个月总缓解率为39%，而标准疗法为23%。其中位无进展生存期为8.5个月，优于 标准疗法的5.5个月。Immuneering特别指出，在超过10%的患者中仅观察到两种3级不良事件，即中性粒 细胞减少症和贫血。 尽管atebimetinib的数据表现良好，但投资者可能将其与处于开发阶段的其他胰腺癌一线疗法进行对比， 例如Verastem的avutometinib联合defactinib方案以及Revolution Medicines的daraxonarasib。其中， avutometinib联合疗法此前报告的总缓解率达83%，daraxonarasib则为55%。不过，Verastem和Revolution Medicines所公布结果的中位随访时间相对较短。 该公司报告称，接受atebimetinib联合改良版吉西他滨/白蛋白结合型紫杉醇治疗的患者，12个月总生存 率为64%。公司指出，目前标准疗法在12个月的总生存率基准为35%。 生物技术公司Immuneering Corp.(IMRX.US)在周三盘后交易中暴跌约21%，此前其公布了atebimetinib作 为胰腺癌一线疗法的2 ...

Core Insights - Immuneering Corporation announced positive overall survival (OS) and safety data from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer patients, showing a 64% OS at 12 months [1][2][6] Clinical Trial Results - The trial involved 34 patients with a median follow-up of over 13 months, with the median OS not yet reached as of the data cutoff on December 15, 2025 [6][7] - The OS rates at various time points were significantly higher than the standard of care benchmark from the MPACT study: - 64% at 12 months vs. 35% - 83% at 9 months vs. ~47% - 94% at 6 months vs. 67% [6][7] - The confirmed overall response rate (ORR) was 39% at 12 months compared to 23% for the standard of care, and the disease control rate (DCR) was 81% vs. 48% [6][7] Safety Profile - The combination therapy demonstrated a favorable tolerability profile, with only neutropenia and anemia observed at Grade 3 in more than 10% of patients, which are common with standard chemotherapy [9][11] Future Plans - The company plans to initiate a pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026, with overall survival as the primary endpoint [2][8] - An expanded cohort of over 50 patients is expected to be reported in the first half of 2026, which includes the original 34 patients [10][17] About Atebimetinib - Atebimetinib is a Deep Cyclic Inhibitor targeting MEK, designed to improve durability and tolerability in cancer treatment, particularly for MAPK pathway-driven tumors like pancreatic cancer [13][14]

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. “We are ...

– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them ...

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by c ...

Core Insights - Immuneering Corporation is a clinical-stage oncology company focused on developing innovative cancer treatments to improve patient survival and quality of life [3] Company Presentation - Immuneering will present at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 4, from 11:10 to 11:30 a.m. ET [2] - The presentation will be available via live webcast and archived on the company's Investor Relations website [2] Product Development - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [3] - Atebimetinib is designed to be an oral, once-daily medication that enhances durability and tolerability across various cancer indications, particularly those driven by the MAPK pathway [3]